Polysaccharide from Atractylodes macrocephala Koidz. protects against avian pathogenic Escherichia coli-induced intestinal barrier Dysfunction via Suppressing PI3K/Akt-Mediated Claudin-2 upregulation

Avian pathogenic Escherichia coli (APEC) is a major cause of intestinal disease in poultry, damaging the gut lining and allowing harmful bacteria and toxins to leak into the bloodstream. This study investigated whether a polysaccharide extract from the traditional Chinese medicinal herb Atractylodes macrocephala Koidz. (AMKP) could protect the intestinal barrier against APEC-induced injury. The researchers found that APEC infection activates the PI3K/Akt signaling pathway, which in turn drives abnormal upregulation of claudin-2 — a tight junction protein that, when overexpressed, makes the intestinal barrier leaky rather than protective. AMKP treatment suppressed this PI3K/Akt-claudin-2 axis, preserving tight junction integrity and reducing barrier dysfunction. The findings suggest that plant-derived polysaccharides can act on specific molecular signaling nodes rather than simply providing nonspecific anti-inflammatory cover. This is meaningful for poultry health because intestinal barrier failure in APEC infection leads to systemic disease, poor growth, and significant economic losses in the industry. Broadly, the work adds mechanistic detail to the growing evidence that natural polysaccharides are pharmacologically active compounds with defined intracellular targets.

• APEC infection induced upregulation of claudin-2 in intestinal epithelial cells, and this upregulation was dependent on PI3K/Akt pathway activation — consistent with claudin-2 acting as a permeability-promoting tight junction protein rather than a barrier-sealing one.
• AMKP treatment suppressed PI3K/Akt phosphorylation and consequently reduced claudin-2 protein levels, restoring tight junction architecture and attenuating epithelial barrier dysfunction in the APEC-challenged model.
• Pharmacological inhibition of PI3K (using a pathway inhibitor as a mechanistic probe) recapitulated the protective effects of AMKP, providing causal evidence that the PI3K/Akt–claudin-2 axis is the operative target through which the polysaccharide exerts its barrier-protective action.

This was a preclinical mechanistic study using an APEC-induced intestinal barrier dysfunction model, likely combining in vitro intestinal epithelial cell challenge with in vivo poultry infection based on the journal context and scope. The intervention was treatment with AMKP (polysaccharide extracted from Atractylodes macrocephala Koidz.) administered at defined concentrations alongside or prior to APEC challenge. Key readouts included tight junction protein expression (claudin-2 and likely other claudins/occludin/ZO-1), PI3K/Akt phosphorylation status, and barrier integrity markers. Specific sample sizes, dosing concentrations, and follow-up durations are reported in the primary article but were not fully extractable from the available abstract metadata.

Because this is a preclinical study in poultry or poultry-derived cell models, direct translation to human intestinal disease requires substantial additional work, and results cannot be assumed to generalize across host species or pathogen types. The study identifies PI3K/Akt–claudin-2 suppression as the mechanism, but does not resolve whether AMKP acts directly on PI3K (e.g., as a kinase inhibitor) or upstream via pattern-recognition receptor modulation, leaving the proximal molecular target undefined. The optimal dose range, pharmacokinetics, and bioavailability of AMKP in vivo are not established, which limits any practical application inference. A logical next experiment would be a dose-response study in a live poultry APEC infection model with gut permeability assays (e.g., FITC-dextran flux) and microbiome profiling to determine whether barrier protection is accompanied by compositional shifts in the intestinal microbiota.

This article extends the corpus's investigation of natural compound-mediated gut barrier protection by providing a defined signaling mechanism — PI3K/Akt-driven claudin-2 upregulation — rather than a purely descriptive barrier-protective effect, paralleling the polysaccharide work in [§118], which similarly examines how a plant-derived mannan modulates gut pathology through immunological and structural pathways. The PI3K/Akt axis targeted here also appears in [§62], where fungal compounds suppress disease progression through the same pathway in a different disease context, reinforcing PI3K/Akt as a cross-context therapeutic node for natural polysaccharides. The focus on claudin-specific tight junction regulation distinguishes this work from studies addressing barrier dysfunction through metabolic or microbiota-mediated routes, such as [§148], which examines dietary starch and gut leakiness via lipid and microbiome mechanisms. Together, these articles collectively support a model in which diverse natural compounds converge on overlapping but mechanistically distinct nodes of intestinal barrier regulation, with the present study contributing the clearest evidence to date for claudin-2 as an actionable downstream target in pathogen-induced barrier failure.

• Anti-inflammatory and gut microbiota-modulating effects of a novel mannan from Scilla scilloides on DSS-induced colitis in mice
  Direct structural parallel: both study plant-derived polysaccharides protecting gut integrity, making comparison useful for understanding whether barrier protection is a shared class effect of polysaccharides or mechanism-specific.
• Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function
  Saccharomyces boulardii also acts on intestinal barrier function via tight junction modulation; comparing mechanisms reveals whether probiotic and polysaccharide interventions converge on the same claudin/occludin targets or operate through distinct pathways.
• Dietary Intervention with Brown Top Millet Starch Ameliorates Dyslipidaemia and Gut Leakiness in High Fat Diet Fed Models
  Also examines gut leakiness in a non-human model using a dietary natural compound intervention, providing a useful comparator for how different compound classes (starch vs. polysaccharide) and different challenge models (high-fat diet vs. bacterial infection) shape barrier outcomes.
• Eubacterium rectale Mitigates Inflammatory Bowel Disease via Modulation of Glutamine Metabolism Through the GLS2 and NF-κB Pathway
  Addresses gut barrier-relevant pathology through a defined molecular pathway (GLS2/NF-κB) using a microbial agent, offering a mechanistic contrast to PI3K/Akt-claudin signaling and helping readers triangulate which pathway is more tractable for therapeutic targeting.